Canaccord Genuity Reiterates a 'Buy' on Vivus, Inc. (VVUS); Slight Shift in Strategy for Qnexa Resubmission; FDA Feedback Can Only Help
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Vivus, Inc. (Nasdaq: VVUS), price target $15.
Canaccord analyst says, "We are bullish on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We are bullish on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
